Health Canada Reviewing GLP-1 Aspiration Pneumonia Anesthesia Risk

Health Canada has opened a new safety and effectiveness review of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) related to aspiration pneumonia during general anesthesia or deep sedation, according to the regulator's Summary Basis of Decision record for Mounjaro [Source: dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD00629].

What the review covers

The Post-Authorization Activity Table for Mounjaro indicates the review was started between November 1 and November 30, 2024 [Source: dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD00629]. Health Canada describes aspiration pneumonia as a lung infection caused by unintentional inhalation of stomach contents, such as food or liquid, into the lungs [Source: dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD00629].

The review is listed under Mounjaro's post-authorization activity because tirzepatide falls within the GLP-1 receptor agonist class covered by the assessment [Source: dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD00629]. The same class includes semaglutide products sold in Canada as Ozempic, Wegovy and Rybelsus.

Recent label changes already on file

Health Canada's record for Mounjaro shows two prior Level II Safety Supplements that updated the product monograph with new safety information. One supplement (SNDS #276224, filed June 16, 2023) resulted in a Notice of Compliance issued November 1, 2023, with modifications to the Warnings and Precautions and Adverse Reactions sections of the product monograph [Source: dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD00629]. A second safety supplement (SNDS #283593, filed February 16, 2024) led to a further NOC on July 10, 2024, with additional updates to the same sections [Source: dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD00629].

Products covered on the Canadian market

The Mounjaro record lists multiple Drug Identification Numbers spanning strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg of tirzepatide in subcutaneous solution form [Source: dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD00629]. The most recent DIN series (02551950 through 02552000) had a date of first sale of December 10, 2024 [Source: dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD00629].

Context: drug-plan coverage debate continues

The safety review is running in parallel with ongoing coverage deliberations at Canada's Drug Agency. A draft CDA report recommended public health plans cover Mounjaro for adults with type 2 diabetes, provided Eli Lilly offers a discount [Source: theglobeandmail.com/business/economy/article-canada-drug-agency-mounjaro-recommendation-type-2-diabetes]. At higher dosages, the report generally recommended public plans seek a discount of 25 to 49 per cent off the list price of Mounjaro [Source: theglobeandmail.com/business/economy/article-canada-drug-agency-mounjaro-recommendation-type-2-diabetes].

The Globe and Mail reported Mounjaro's list price was between $300 and $540 as of the beginning of 2026, depending on dosage, and that figure excludes pharmacy and distributor markups [Source: theglobeandmail.com/business/economy/article-canada-drug-agency-mounjaro-recommendation-type-2-diabetes]. Current pharmacy prices tracked on GLP1Prices.ca range from $283.08 to $813 per unit across strengths, reflecting markups and pack-size variations not captured in the list price. The CDA report also noted that public plans spent $794-million on Ozempic in 2024, and estimated Mounjaro coverage could cost public plans about $1.97-billion over three years [Source: theglobeandmail.com/business/economy/article-canada-drug-agency-mounjaro-recommendation-type-2-diabetes].

What happens next

Health Canada's safety reviews are a formal process used to examine potential signals before deciding whether labelling, risk communications or other regulatory actions are warranted. The department has not yet announced conclusions or next steps from the aspiration pneumonia review in the Mounjaro SBD record, which was last updated October 24, 2025 [Source: dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD00629].

Canadians tracking class-wide developments can monitor price movements across brands including Zepbound, follow upcoming generic filings on our generic semaglutide tracker, or consult the insurance coverage checker for plan-level details.

This article is for informational purposes only and does not constitute medical advice.